FFRangio System vs VX1+

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by CathWorks (acquired by Medtronic)
VS
by Volta Medical

AI Verdict

These tools are adjacent rather than direct competitors, as they address distinct clinical needs within cardiology. The FFRangio System focuses on optimizing PCI decisions for coronary artery disease by providing wire-free FFR guidance. In contrast, VX1+ assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for arrhythmias like atrial fibrillation.

Choose FFRangio System if…

Choose the FFRangio System if you need a non-invasive, wire-free solution to assess coronary artery disease and optimize percutaneous coronary intervention (PCI) decisions. This tool is ideal for quickly obtaining accurate multi-vessel FFR results and advanced insights without the need for pressure wires or vasoactive drugs, streamlining your cath lab workflow for CAD patients.

View FFRangio System →

Choose VX1+ if…

Choose VX1+ if you are an electrophysiologist performing cardiac ablation procedures for atrial fibrillation or atrial tachycardia and require real-time, AI-powered assistance. This software is best suited for identifying abnormal electrograms and spatio-temporal dispersed electrograms (DEs) to precisely guide ablation, enhancing procedural efficiency and outcomes.

View VX1+ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature FFRangio System VX1+
Pricing Contact vendor for pricing information. Unknown
Deployment SaaS, on-prem, hybrid Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs.
BAA Available Yes AI-estimated Unknown
FDA Status Cleared AI-estimated Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

FFRangio System

The FFRangio System boasts an intuitive user interface and seamless integration with cath lab equipment and PACS, with user testimonials highlighting its smooth workflow integration and user-friendliness after minimal training. While VX1+ also emphasizes a simple interface and fast learning curve, Tool A's documented comprehensive integration within the cath lab environment and positive user feedback give it a slight edge.

Clinical Value

FFRangio System

The FFRangio System offers significant clinical value by providing wire-free and drug-free FFR guidance with a diagnostic accuracy of 93% compared to invasive FFR, and has shown comparable one-year major adverse cardiac event rates. In contrast, while VX1+ has promising proof-of-concept study results, its FDA clearance explicitly states that the clinical significance of its software for improving ablation outcomes has 'not been established by clinical investigations.'

Pricing & Value

Tie

Neither tool provides publicly available pricing information, making a direct comparison of their cost-effectiveness impossible. Both products claim to offer value through improved procedural efficiency and reduced risks, but without specific financial data or detailed ROI studies, a definitive winner cannot be determined.

Enterprise Readiness

FFRangio System

The FFRangio System demonstrates strong enterprise readiness through its ISO 27001 and ISO 13485 certifications, indicating robust information security and quality management systems. Furthermore, its acquisition by Medtronic provides significant corporate backing and potential for broader integration and support within healthcare enterprises. While VX1+ is FDA cleared and CE marked, it does not explicitly state ISO 27001 certification.

Innovation

FFRangio System

Both tools are highly innovative, leveraging AI for real-time clinical decision support. However, the FFRangio System's 'wire-free and drug-free' approach to FFR measurement represents a more fundamental paradigm shift by transforming a previously invasive diagnostic procedure into a non-invasive one, directly reducing patient risk and discomfort.

Support & Docs

Tie

Both companies provide essential support resources, including access to user manuals and contact information on their respective websites. There is insufficient information available to differentiate between the quality, breadth, or responsiveness of their support services or documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature FFRangio System VX1+
Name FFRangio System VX1+
Company CathWorks Volta Medical
Primary Purpose Delivers wire-free and drug-free 3D FFR guidance, providing accurate multi-vessel FFR results and advanced insights to quickly optimize and confirm PCI decisions for patients with coronary artery disease. AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.
Target Medical Specialty Cardiology Cardiology
Key Feature (Example) Real-time FFRangio values at every point on the coronary tree; Eliminates the need for invasive pressure wires, drugs, or a guide catheter. Real-time manual or automatic annotation of 3D anatomical and electrical maps; Identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures.

Videos

Demos, reviews, and walkthroughs featuring FFRangio System and VX1+.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The FFRangio System is designed to provide wire-free and drug-free 3D FFR guidance, optimizing and confirming PCI decisions for patients with coronary artery disease. The VX1+ is an AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.
The FFRangio System is deployed on-premise and integrates seamlessly with cath lab equipment and C-arm angiography systems. The VX1+ is a software application that integrates with existing EP recording and 3D mapping systems, including specific data acquisition systems like Boston Scientific LabSystem Pro and Abbott EnSite X 3D mapping system.
The FFRangio System utilizes artificial intelligence to aid in quick angiogram analysis, providing real-time FFRangio values and advanced insights for PCI optimization. The VX1+ offers AI-driven insights for real-time manual or automatic annotation of 3D anatomical and electrical maps, assisting electrophysiologists in identifying spatio-temporal dispersed electrograms during AF and AT procedures.
The FFRangio System aims to eliminate the need for invasive pressure wires, drugs, or a guide catheter for FFR assessment. The VX1+ assists during already invasive cardiac ablation procedures by providing AI-powered insights for electrogram identification.
The FFRangio System analyzes angiographic images to derive physiological data like FFRangio values at every point on the coronary tree. The VX1+ analyzes electrogram data to identify abnormal electrical activity, specifically spatio-temporal dispersed electrograms (DEs), during cardiac ablation procedures.
The FFRangio System is ISO 27001 certified for information security, and while HIPAA compliance is unknown, it handles protected health information (PHI). For VX1+, HIPAA compliance and a Business Associate Agreement (BAA) are expected for a medical device handling patient data in U.S. healthcare settings, though not explicitly stated.
AI Tool Finder
AI-powered search. Results may not be comprehensive.